社区

美国制药公司查尔斯河实验室宣布签署一项约束性要约，以4.48亿欧元现金（约5.1亿美元）收购法国合同研究机构 Citoxlab，本次拟交易预计于2019年第二季度完成。 $查尔斯河(CRL)$

Charles River Laboratories International, Inc. announced today that it has signed a binding offer to acquire Citoxlab for €448 million in cash (or approximately $510 million based on current exchange rates), subject to customary closing adjustments.

马萨诸塞州 WILMINGTON。---(商业前景)---- 查尔斯河今天宣布，它已签署一项约束性要约，以4.48亿欧元现金（或根据当前汇率约5.1亿美元）收购 Citoxlab，但需按照惯例进行结算调整。

The proposed transaction is expected to close in the second quarter of 2019, subject to labor consultations, regulatory requirements, and customary closing conditions. Upon completion of the labor consultations, Citoxlab’s shareholders are expected to enter into a definitive purchase agreement.

本次拟交易预计于2019年第二季度完成，具体以劳动咨询、监管要求、惯常交割条件为准。劳动协商完成后，西乐斯实验室的股东有望达成最终购买协议。

关于Citoxlab

Citoxlab is a premier, non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the proposed acquisition of Citoxlab would further strengthen Charles River’s position as the leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which would enhance the Company’s ability to partner with clients across the drug discovery and development continuum.

西药实验室是一家一流的、非临床合同研究组织（ CRO ），专业从事规范的安全评估服务、非规范的发现服务、医疗器械检测。通过在欧洲和北美开展业务，拟收购西考昔将通过扩大其科学组合和地理足迹，进一步巩固 Charles River 作为领先的全球早期CRO的地位，从而增强公司与客户在药物发现和开发连续性方面的合作能力。

James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “The proposed acquisition of Citoxlab would expand and solidify Charles River’s position as the partner of choice for our clients’ early-stage research needs, at a time when we believe there continues to be significant demand for outsourced services from both biotechnology and pharmaceutical companies.

Charles River Laboratories 董事长、总裁兼首席执行官 James C . Foster 评论道：“拟议收购 Citoxlab 将扩大和巩固 Charles River 作为客户早期研究需求首选合作伙伴的地位。目前，我们认为生物技术和制药公司对外包服务的需求仍然很大。

Citoxlab would be an exceptional strategic fit for Charles River because it incorporates the key attributes we require in an acquisition: scientific expertise, complementary capabilities, talented people, and access to growing end markets. The proposed acquisition would also enhance our geographic footprint, particularly in Europe, and our access to a growing biotechnology client base, enabling Charles River to provide a broader range of services proximate to our clients – both large and small.”

Citoxlab 将是 Charles River 的一项特殊战略，因为它包含了收购所需的关键属性：科学专业知识、互补能力、人才以及进入不断增长的终端市场。拟议中的收购还将增强我们在地理上的足迹，尤其是在欧洲，以及我们获得日益增长的生物技术客户基础的机会，使 Charles River 能够为我们的客户提供更广泛的服务，无论是大的还是小的。”